VolitionRx Ltd (VNRX) stock
VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.19−0.01 (-5.56%)
Close on Nov 17, 2026Market cap $2.58MP/E –Yield –
VolitionRx total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
VolitionRx's total debt was $7.05M at Jun 30, 2026. For fiscal 2025 it was $6.71M, up 39.4% from the year before. The highest annual figure on record is $6.71M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.71M | +39.4% |
| FY2024 | Dec 31, 2024 | $4.81M | -0.4% |
| FY2023 | Dec 31, 2023 | $4.83M | +25.6% |
| FY2022 | Dec 31, 2022 | $3.85M | +25.3% |
| FY2021 | Dec 31, 2021 | $3.07M | -11.0% |
| FY2020 | Dec 31, 2020 | $3.45M | +21.3% |
| FY2019 | Dec 31, 2019 | $2.84M | +18.4% |
| FY2018 | Dec 31, 2018 | $2.40M | +36.7% |
| FY2017 | Dec 31, 2017 | $1.76M | +279.7% |
| FY2016 | Dec 31, 2016 | $462.68K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.05M | +3.9% |
| Q1 FY2026 | Mar 31, 2026 | $7.29M | +14.0% |
| Q4 FY2025 | Dec 31, 2025 | $6.71M | +39.4% |
| Q3 FY2025 | Sep 30, 2025 | $6.48M | +34.9% |
| Q2 FY2025 | Jun 30, 2025 | $6.79M | +38.3% |
| Q1 FY2025 | Mar 31, 2025 | $6.39M | +41.4% |
| Q4 FY2024 | Dec 31, 2024 | $4.81M | -0.4% |
| Q3 FY2024 | Sep 30, 2024 | $4.80M | +43.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.91M | +34.4% |
| Q1 FY2024 | Mar 31, 2024 | $4.52M | +23.2% |
| Q4 FY2023 | Dec 31, 2023 | $4.83M | +25.6% |
| Q3 FY2023 | Sep 30, 2023 | $3.34M | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.65M | +29.1% |
| Q1 FY2023 | Mar 31, 2023 | $3.67M | +9.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.85M | +25.3% |
| Q3 FY2022 | Sep 30, 2022 | $3.34M | +19.8% |
| Q2 FY2022 | Jun 30, 2022 | $2.83M | -7.0% |
| Q1 FY2022 | Mar 31, 2022 | $3.37M | +4.1% |
| Q4 FY2021 | Dec 31, 2021 | $3.07M | -11.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.79M | +7.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.04M | +16.7% |
| Q1 FY2021 | Mar 31, 2021 | $3.23M | +20.8% |
| Q4 FY2020 | Dec 31, 2020 | $3.45M | +21.3% |
| Q3 FY2020 | Sep 30, 2020 | $2.60M | +12.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.61M | +3.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.68M | +18.1% |
| Q4 FY2019 | Dec 31, 2019 | $2.84M | +18.4% |
| Q3 FY2019 | Sep 30, 2019 | $2.30M | +4.3% |
| Q2 FY2019 | Jun 30, 2019 | $2.52M | +11.5% |
| Q1 FY2019 | Mar 31, 2019 | $2.26M | +27.9% |
| Q4 FY2018 | Dec 31, 2018 | $2.40M | +36.7% |
| Q3 FY2018 | Sep 30, 2018 | $2.21M | +51.4% |
| Q2 FY2018 | Jun 30, 2018 | $2.26M | +87.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.77M | +133.6% |
| Q4 FY2017 | Dec 31, 2017 | $1.76M | +279.7% |
| Q3 FY2017 | Sep 30, 2017 | $1.46M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.20M | – |
| Q1 FY2017 | Mar 31, 2017 | $758.39K | – |
| Q4 FY2016 | Dec 31, 2016 | $462.68K | – |
See a number that looks wrong?